cas 869367-33-9|| where to buy 8-chloro-4-(dimethylaminomethylene)-1-(2-fluoro-6-methoxy-phenyl)-3H-2-benzazepin-5-one

Product Name:8-chloro-4-(dimethylaminomethylene)-1-(2-fluoro-6-methoxy-phenyl)-3H-2-benzazepin-5-one

IUPAC Name:8-chloro-4-[(dimethylamino)methylidene]-1-(2-fluoro-6-methoxyphenyl)-4,5-dihydro-3H-2-benzazepin-5-one

Packing Unit	Available Stock	Price($)
CM1018162-100mg	in stock	ŉưȎ
CM1018162-250mg	in stock	ȎƓƓ
CM1018162-500mg	1-2 Weeks	ǤƓƓǤ
CM1018162-1g	1-2 Weeks	ǤĽƓƓ
CM1018162-5g	1-2 Weeks	ǊĽƓƓ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:869367-33-9; Molecular Formula:C20H18ClFN2O2; Melting Point:-; Smiles Code:COC1=CC=CC(F)=C1C1=NCC(=CN(C)C)C(=O)C2=CC=C(Cl)C=C12; Density:

: Catalog Number:CM1018162; Molecular Weight:372.82; Boiling Point:; MDL No:; Storage:

: Alisertib; Puma Biotechnology announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1 trial will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed on or after first-line platinum-based chemotherapy and immunotherapy. The primary endpoint of the trial is objective response rate, with secondary endpoints of duration of response, disease control rate, progression-free survival and overall survival. Based upon the outcomes of the study, Puma anticipates meeting with the FDA to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer. Alisertib is an orally active and selective Aurora A kinase inhibitor, which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.